Photobiomodulation and neuro research

Research with Vielight technology

For over a decade, we’ve partnered with world-class educational and healthcare institutions.
Today, our technology remains the gold standard, powering more published photobiomodulation research than any other.

Conduct Research with Us Join a Clinical Trial

800 +

clinical research participants

30 +

published research studies

3

medical device  licenses

Published research with Vielight

Brain Network Efficiency & Connectivity

Improved large-scale brain network connectivity and efficiency on fMRI. (Liebel et al., 2025)

See research study

Memory & Mood

Improved ADAS-cog scores, cerebral perfusion, default-mode network connectivity. (Chao et al., 2019, UCSF)

See research study

Mobility and Cognition

Improved mobility and cognition instead of the usual decline seen over time. 10-meter walking speed rose from 1.12 to 1.70 m/s after 12 weeks (≈50% faster) (Liebert et al., 2021)

See research study

Reaction time and balance

Reaction time showed a large effect size (g = 0.75) and reactive balance (MiniBEST) improved with g = 0.63 relative to baseline. (Johnson et al., 2024)

See research study

Creativity

Creativity scores improved with a large effect size (η²p ≈ 0.24) compared with sham stimulation, indicating stronger idea fluency and originality. (Peña et al., 2024)

See research study

Neural energy 

Boosted global network efficiency in alpha/gamma bands across up to ~90% of tested connectivity densities, with no such changes under sham. (Zomorrodi et al., 2019)

See research study

Cognition

Montreal Cognitive Assessment scores increased by 3.20 points vs 1.97 with placebo after 60 days (Neda et al., 2024)

See research study

Studies with Vielight technology

Filter studies by condition:

See all

Alzheimer’s (Dementia)

Traumatic Brain Injury

Parkinson’s

Mild Cognitive Impairment

Cognitive Enhancement

Viral Immunity

Autism

Neuromodulation

Cellular Enhancement

Long Covid

Brain Fog

PTSD

Upper Respiratory Viral Recovery

Published Studies

Ongoing Studies

Participants

See full research stats

Traumatic Brain Injury Published in 2026

Completed Clinical study (n=26)

Conducted with the

Vielight Neuro Gamma

Utah Neurotrauma Study | Advanced Diffusion MRI & Brain Resilience | Vielight Neuro

Can Vielight "armor" the brain from impacts? A groundbreaking 2026 double-blind study conducted by the University of Utah and BYU, published in the prestigious Journal of Neurotrauma followed 26 NCAA Division I football players over a full season.

In collaboration with the University of Utah, Brigham Young University

Read summary See published study

Traumatic Brain Injury Published in 2025

Completed Clinical trial (n=30)

Conducted with the

Vielight Neuro Gamma

TBI Research: Cerebellar Network Efficiency Improved by Vielight Intranasal-Transcranial Photobiomodulation (itPBM) (n=30)

This n=30 TBI study utilized fMRI to detect neurophysiological changes in the cerebellum before and after intranasal-transcranial photobiomodulation (itPBM) with the Vielight Neuro Gamma. This was conducted by the University of Utah's Traumatic Brain Injury and Concussion Center.

In collaboration with the University of Utah, the University of California Los Angeles

and Mount Sinai Hospital

See summary See published study

Cellular Enhancement Published in 2025

Completed Cellular research

Conducted with the

Vielight Neuro Pro

Cellular Study: Vielight Neuro Pro’s NIR Light Shifts Metabolism in Cancer Cells

The Vielight Neuro Pro 2 enhanced viability in normal cell models at 810 nm wavelength pulsing at 10 Hz. In parallel, we observed that under the right conditions PBM reduced viability or slowed proliferation of cancer-cell models (or modulated malignant behaviour) - underscoring that PBM’s effects are not indiscriminate. This is preliminary research, not a cancer treatment.

See summary Published study link

Brain Fog Published in 2025

Completed Clinical trial (n=39)

Conducted with the

Vielight Neuro Gamma

Research Summary | Brain PBM and Post-Chemotherapy Cognitive Impairment (CRCI)

A new clinical pilot study investigates the potential of near-infrared light therapy for managing cancer-related cognitive impairment (CRCI). Researchers observed significant improvements in memory and mental clarity using the Vielight Neuro Duo 4. Read our full summary of the data, the 40 Hz protocol used, and what these findings mean for the future of neural recovery.

In collaboration with Valenciennes General Hospital, Martinique University Hospital.

Read summary See published study

Cognitive Enhancement Published in 2025

Completed Clinical trial (n=45)

Conducted with the

Vielight intranasal-transcranial technology

Vielight PBM improves Brain Fluid Dynamics (MRI) | Baycrest Hospital

The study, conducted by Baycrest Hospital and Vielight technology on 45 healthy adults (aged 20–32) , compared the effects of Transcranial PBM (tPBM) applied to the forehead against Intranasal PBM (iPBM). The data highlights the remarkable efficiency of the intranasal delivery channel—a core component of Vielight’s patented technology.

In collaboration with Baycrest Hospital.

See summary See published study

Alzheimer’s (Dementia) Published in 2025

Completed Clinical trial (n=24)

Conducted with the

Neuro Gamma

Using Magnetic Resonance Imaging to Explore the Effects of the Vielight Neuro on Brain Activity

At the University of Sydney, researchers asked an important question: if healthy young adults receive a single session with a Vielight 810 nm transcranial device, what changes on fMRI at rest and during a simple finger-tapping task?

In collaboration with the University of Sydney.

See summary See published study

Alzheimer’s (Dementia) Published in 2025

Completed Clinical study

Conducted with the

Neuro Gamma

Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation

This study explored the effects of near-infrared photobiomodulation therapy on 5 patients with mild to moderate dementia. After 12 weeks of treatment with the Vielight Neuro Gamma, patients showed significant cognitive improvements, including better sleep and reduced anxiety.

In collaboration with Harvard Medical School,
and the Boston University School of Medicine

See published study

Alzheimer’s (Dementia) Published in 2025

Completed Clinical study

Conducted with the

Neuro Gamma

Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial

Eight participants diagnosed with dementia were randomized to 12 weeks of usual care or home photobiomodulation treatments. These treatments were administered at home with the Vielight Neuro Gamma. After 12 weeks, there were improvements in ADAS-cog and in the NPI.

In collaboration with the University of California,
and the Veterans Affairs USA

See summary See published study

Traumatic Brain Injury Published in 2025

Completed Clinical trial (n=44)

Conducted with the

Neuro Gamma

Second Phase of Utah TBI Research Strengthens Case for Vielight Neuro in Treating Cognitive Deficits

This TBI study (n=44) with the Neuro Gamma is the largest published clinical trial to report statistically significant improvements on objective cognitive tests after a multi-week PBM intervention in a TBI-related/RHAE population. Larger TBI trials exist with non-Vielight devices, but they did not demonstrate significant clinical (symptom/cognition) gains.

In collaboration with the University of Utah,

and Mount Sinai Hospital

See summary See published study

Cognitive Enhancement Published in 2025

Completed Clinical trial (n=14)

Conducted with the

Neuro Alpha

Reducing PTSD and Enhancing Cognition Published Clinical Study: Transcranial-Intranasal Photobiomodulation | Vielight Neuro

Firefighters endure extreme stress, traumatic events, and irregular schedules that can lead to poor sleep and chronic fatigue, persistent pain, mood dysregulation, PTSD symptoms. Researchers at the University of Utah conducted an n=14 transcranial-intranasal photobiomodulation (itPBM) using the Vielight Neuro Alpha to reduce inflammation, and support brain network function.

In collaboration with the University of Utah,

and Mount Sinai Hospital

See summary See published study

Traumatic Brain Injury Published in 2024

Completed Clinical trial (n=43)

Conducted with the

Neuro Gamma

The Effect of Intranasal Plus Transcranial Photobiomodulation on Neuromuscular Control in Individuals with Repetitive Head Acceleration Events

A University of Utah study explored the effects of the Vielight Neuro Gamma device on brain injuries. The study involved 43 participants with mild traumatic brain injury or related symptoms. Results showed significant improvements in reaction time, grip strength, and balance after 8-10 weeks of at-home photobiomodulation treatment.

In collaboration with the University of Utah,

and Mount Sinai Hospital

See summary See published study

Alzheimer’s (Dementia) Published in 2024

Completed Clinical study (n=14)

Conducted with the

Neuro Gamma

Mild Cognitive Impairment (MCI) Clinical Trial with Intranasal-Transcranial Photobiomodulation

This study investigated the effects of transcranial photobiomodulation on brain function in 14 individuals with mild cognitive impairment (MCI). After 6 weeks of treatment, the active group showed improvements in cognitive performance, brain connectivity, and mitochondrial function, along with favorable changes in blood biomarkers linked to Alzheimer's.

In collaboration with the University of Toronto,
and St. Michael’s Hospital, Unity Health Toronto

See summary See published presentation

Cellular Enhancement Published in 2024

Completed Scientific study

Conducted with the

Neuro Alpha

Raman Spectroscopy Reveals Photobiomodulation-Induced α-Helix to β-Sheet Transition in Tubulins: Potential Implications for Alzheimer’s and Other Neurodegenerative Diseases

This study examines how photobiomodulation affects tubulin, a protein linked to neurodegenerative diseases. The results show that it alters tubulin structure by decreasing α-helix content and increasing β-sheets, which may reduce microtubule stability and promote remodeling, potentially aiding Alzheimer’s treatment.

In collaboration with the Polytechnic University

of Turin (Italy), and the University of Alberta

See published study

Upper Respiratory Viral Recovery Published in 2024

Completed Phase 3 clinical trial (n=294)

Conducted with the

RX Plus

Viral Recovery and Immunity Major PBM Clinical Trial | Vielight RX-Plus (n=294) | Health Canada Medical Device License

This is the world's biggest, successful PBM clinical trial. It tested the Vielight RX-Plus, the only photobiomodulation device with published results for viral recovery and immunity, on 294 adults with moderate-to-severe COVID-19. Photobiomodulation sped up recovery for those with 0-7 days of symptoms, reducing respiratory issues, headaches, chest congestion, body aches, and taste problems, likely by lowering cytokine levels.

In collaboration with the University of Johannesburg

See summary See published study

Traumatic Brain Injury Published in 2023

Completed Clinical study

Conducted with the

Neuro Gamma

Transcranial Photobiomodulation Treatment: Significant Improvements in Four Ex-Football Players with Possible Chronic Traumatic Encephalopathy

A study on ex-football players with traumatic encephalopathy syndrome explored transcranial photobiomodulation. After 6 weeks of treatment, participants showed notable improvements in cognition, mood, and behavior. MRI scans revealed increased brain connectivity and higher N-acetyl-aspartate levels, suggesting that photobiomodulation has therapeutic benefits.

In collaboration with Harvard Medical School,
and the Boston University School of Medicine

See published study

Cognitive Enhancement Published in 2023

Completed Clinical study (n=58)

Conducted with the

Neuro Gamma

Enhancement of Divergent Creative Thinking After Transcranial Near-Infrared Photobiomodulation Over the Default Mode Network

A study with 58 healthy participants explored the impact of the Neuro Gamma device on creativity. The device targets the brain's Default Mode Network, associated with creative thinking. Results showed improvements in verbal and visual divergent thinking scores, with large effects on originality and fluency.

In collaboration with the University of Deusto (Spain), the University of Montpellier (France),

and Pennsylvania State University

See summary See published study

Cellular Enhancement Published in 2022

Completed Scientific study

Conducted with the

Neuro Alpha

Near-Infrared Photobiomodulation of Living Cells, Tubulin, and Microtubules In Vitro

This study investigates the effects of photobiomodulation on living cells, tubulin, and microtubules. Photobiomodulation influenced tubulin polymerization, slowing it in lower concentrations and accelerating it at higher ones. These findings suggest that photobiomodulation can modulate cellular processes and provide insights for improving photobiomodulation treatments for neurodegenerative diseases.

In collaboration with Princeton University,

the University of Alberta, and the

Polytechnic University of Turin (Italy)

See published study

Autism Published in 2022

Completed Clinical study (n=21)

Conducted with the

Neuro Duo

Transcranial Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder (ASD): A Retrospective Study

This study, led by Dr. Stefano Pallanti, explored the effects of photobiomodulation on Autism Spectrum Disorder using the Neuro Duo device. It involved 21 children aged 5 to 15, who used the device daily for six months with two protocols: Alpha (10 Hz) and Gamma (40 Hz). The results showed significant improvements, including reduced ASD severity, noncompliant behavior, parental stress, and cognitive rigidity, as well as better attentional functions and sleep quality.

In collaboration with the Neurodevelopment

Division, Istituto di Neuroscienze (Italy)

See summary See published study

Parkinson’s Published in 2021

Completed Clinical study (n=14)

Conducted with the

Neuro Gamma

Improvements in Parkinson’s disease using Photobiomodulation

A study by Dr. Ann Liebert at the University of Sydney tested the Vielight Neuro Gamma device for Parkinson’s disease. Twelve participants with idiopathic Parkinson’s showed significant improvements in mobility, motor skills, balance, and cognition after 12 weeks of photobiomodulation therapy, with benefits lasting up to a year with continued home treatment. No side effects were observed.

In collaboration with the University of Sydney

See summary See published study

Traumatic Brain Injury Published in 2020

Completed Clinical study Conducted with the

Neuro Gamma and the Neuro Alpha

Changes in Brain Function and Structure After Self-Administered Home Photobiomodulation Treatment in a Concussion Case

This study investigates the effects of photobiomodulation on a 23-year-old hockey player with concussion-related symptoms. After 8 weeks of treatment using the Neuro Gamma and Neuro Alpha devices, he showed improvements in brain volume, functional connectivity, and cognitive function, including memory, attention, and processing speed. His headaches also decreased.

In collaboration with the University of California,
and the Veterans Affairs USA

See published study

PTSD Published in 2019

Completed Clinical study (n=47)

Conducted with the

MIP 810 and MIP 633

Scalp Application of LED Therapy to Improve Thinking and Memory in Veterans With Gulf War Illness

In 2014, the VA Boston Healthcare System conducted a study involving 47 veterans with Gulf War illness. The study tested Vielight’s intranasal red and near-infrared light therapy to support cognitive function and improve blood flow. The painless, non-invasive transcranial LED treatment generated no heat. All devices used were approved by the VABHS safety committee. The treatment was classified by the FDA as low-risk.

In collaboration with the Veterans Affairs USA

See summary See published study

Cognitive Enhancement Published in 2019

Completed Clinical study (n=20)

Conducted with the

Neuro Gamma

Pulsed NIR Transcranial-Intranasal Photobiomodulation Significantly Modulates Neural oscillations

The Neuro Gamma is the first brain photobiomodulation device to demonstrate neuromodulation. This study looked at the effects of this device on brain activity in 20 healthy adults. Brain network analysis showed improved connectivity, especially in the alpha and gamma bands. These results suggest that active photobiomodulation enhances brain function and connectivity.

In collaboration with the University of Toronto,

and the Centre for Addiction and Mental Health

See summary See published study

PTSD Published in 2019

Completed Clinical study

Conducted with the

Neuro Alpha

Improvements in Gulf War Illness Symptoms After Near-Infrared Transcranial and Intranasal Photobiomodulation: Two Case Reports

This study examines the effects of photobiomodulation therapy on two Gulf War veterans suffering from Gulf War illness, a condition marked by symptoms like fatigue, pain, cognitive dysfunction, and more. The veterans used the Neuro Alpha every other day for 12 weeks, with results showing symptom improvements. One veteran no longer met the criteria for Gulf War illness, and the other saw significant reductions in fatigue, pain, and cognitive symptoms.

In collaboration with the University of California,
and the Veterans Affairs USA

See published study

Viral Immunity Published in 2018

Completed Scientific study

Conducted with the

MIP 470-633-655-810

Antimicrobial Photodynamic Inactivation Mediated by Tetracyclines in Vitro and in Vivo: Photochemical Mechanisms and Potentiation by Potassium Iodide

This study looks at how tetracyclines, like demeclocycline and doxycycline, work as antibiotics and are activated by light. Adding potassium iodide (KI) boosted their ability to kill bacteria, including E. coli and MRSA, even without oxygen. KI helped tetracyclines work better, especially in a mouse wound model, preventing bacterial regrowth.

In collaboration with Harvard Medical School

See published study

Viral Immunity Published in 2017

Completed Scientific study

Conducted with the

MIP 470-633-655-810

Antimicrobial Blue Light Therapy for Infectious Keratitis: Ex Vivo and In Vivo Studies

This study investigates the use of antimicrobial blue light (aBL) to treat infectious keratitis caused by Pseudomonas aeruginosa. Using ex vivo and in vivo models, aBL treatment significantly reduced bacterial levels in the cornea after a single exposure, though infection recurred after 24 hours. The study suggests that aBL could be a promising treatment for keratitis.

In collaboration with Harvard Medical School

https://iovs.arvojournals.org/article.aspx?articleid=2600146

Viral Immunity Published in 2016

Completed Scientific study

Conducted with the

MIP 470-633-655-810

Antimicrobial blue light inactivation of Candida albicans: In vitro and in vivo studies

This study investigates the effectiveness of antimicrobial blue light (aBL) for treating Candida albicans infections in vitro and in a mouse burn model. The results show that C. albicans is 42 times more susceptible to aBL than human cells, with no significant development of resistance after repeated exposures. A single exposure of aBL reduced fungal burden in infected mouse burns by 1.75-log10. These findings suggest that aBL could be a promising treatment for C. albicans infections.

In collaboration with Harvard Medical School

See published study

Traumatic Brain Injury Published in 2024

Traumatic Brain Injury Recovery with Photobiomodulation: Cellular Mechanisms, Clinical Evidence, and Future Potential

This study examines the potential of transcranial photobiomodulation as a treatment for Traumatic Brain Injury (TBI). Photobiomodulation targets TBI’s key issues such as axonal damage, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The review suggests photobiomodulation could be a promising therapy, with clinical studies supporting its effectiveness, though outcomes vary based on factors like light wavelength, dose, and frequency.

Study conducted by Vielight Inc.

See published study

Alzheimer’s (Dementia) Published in 2024

Completed Review study

Conducted with the

Neuro Gamma

Modifying Alzheimer’s disease pathophysiology with photobiomodulation: model, evidence, and future with EEG-guided intervention

This study examines Alzheimer's Disease pathophysiology, focusing on genetic factors, mitochondrial dysfunction, and protein accumulation. It proposes photobiomodulation as a promising treatment to address these issues and improve cognitive function. The use of EEG data helps personalize photobiomodulation therapy.

Study conducted by Vielight Inc.

See published study

Traumatic Brain Injury Ongoing

In progress Clinical study (n=20)

Conducted with the

Neuro Alpha

Transcranial Photobiomodulation to Improve Cognition in TBI, With Pre-/Post- fMRI Scans: A Pilot, Sham-Controlled Study

This study investigates transcranial photobiomodulation for improving cognition in veterans with mild to moderate traumatic brain injury. Participants receive at-home treatments over two 5-week periods. Using a randomized, sham-controlled design, the study evaluates changes in brain function, connectivity, and structure via neuropsychological tests and MRI scans, aiming to assess cognitive improvements.

In collaboration with the Boston Veterans Affairs Research Institute

See study information

Neuromodulation Pre-publication

In progress Clinical study

Conducted with the

Neuro Alpha

Modulation of cortical oscillations using 10hz near-infrared transcranial and intranasal photobiomodulation: a randomized sham-controlled crossover study

This study explored the effects of transcranial photobiomodulation on brain oscillations in 25 healthy volunteers. Participants received four types of stimulation. Results showed significant changes in brainwave frequencies (theta, alpha, beta, gamma) after active stimulations, with the effects varying based on stimulation type and location. The intranasal LED stimulation notably increased beta and gamma waves.

Study conducted by Vielight Inc.

See published abstract

Long Covid Published January 2026

In progress Clinical trial (n=43)

Conducted with the

Neuro RX Gamma

Vielight Neuro and Post-COVID Cognitive Impairment | Long-Covid | Brain Fog | The Lancet

Published in The Lancet’s eClinicalMedicine: A gold-standard, randomized, double-blind, sham-controlled trial (n=43) evaluating the efficacy of the Vielight Neuro RX Gamma for Long COVID cognitive dysfunction.

Study conducted by Vielight Inc.

The Lancet Press Release Full Published Study Link

Parkinson’s Ongoing

In progress Phase 2 clinical trial (n=135)

Conducted with the

MIP 810

Pilot Intervention With Near Infrared Stimulation: Revitalizing Cognition in Older Adults and Those With Parkinson Disease

This pilot study examines the effects of near-infrared stimulation on cognition and mood in older adults without dementia. The study randomizes 135 participants into treatment groups and evaluate brain imaging and cognitive measures before and after 12 weeks of transcranial and intranasal near-infrared stimulation, with both lab and home-based treatments.

In collaboration with the University of Florida

See study information

Parkinson’s Registered

In progress Clinical study

Conducted with the

Neuro Gamma

Evaluation of dose of Photobiomodulation (Light) Therapy and Physiotherapy for Improving Quality of Life Outcomes and Mobility in Parkinson’s Disease

This study tests photobiomodulation therapy for Parkinson's using two light devices: Vielight Neuro Gamma (home use) and Irradia Mid-Laser 2.5 (clinic-based). Participants in Brisbane, Sydney, and Adelaide will receive escalating treatments over 12 weeks. Brisbane participants will be randomized to either device, Sydney participants will use the Irradia device, and Adelaide participants will use both devices.

In collaboration with the University of Sydney, and the University of Queensland (Brisbane)

See study information

Alzheimer’s (Dementia) Ongoing

In progress Phase 3 clinical trial (n=228)

Conducted with the

Neuro RX Gamma

Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer’s Disease

This study investigates the use of the Vielight Neuro RX Gamma in moderate to severe Alzheimer's Disease. The study will enroll 228 patients across 12 sites in Canada and the U.S., with follow-up assessments at 12 and 24 weeks. Participants will use the device for 20 minutes daily, 6 days a week, over two 12-week treatment phases.

In collaboration with the University of Toronto,
and St. Michael’s Hospital, Unity Health Toronto

See study information

Alzheimer’s (Dementia) Results analysis

In progress Clinical study

Conducted with the

Neuro Gamma

Examining the Impact of Photobiomodulation on Cognition, Behavior, and Biomarkers of Alzheimer’s Disease

This study aims to evaluate the safety, tolerability, and effects of photobiomodulation on cognitive function, behavioral symptoms, and biomarkers in patients with mild-to-moderate Alzheimer's disease. Participants will use the Vielight Neuro Gamma for 20 minutes daily over 16 weeks. Biomarkers of inflammation, neurodegeneration, and neurotrophic factors will be measured.

In collaboration with the University of California, and the Veterans Affairs USA

See study information

Alzheimer’s (Dementia) Registered

In progress Phase 3 clinical trial (n=168)

Conducted with the

Neuro Gamma

Revitalizing Cognition in Older Adults at Risk for Alzheimer’s Disease With Near-Infrared Photobiomodulation

This study tests near-infrared light therapy in 168 adults aged 65–89 at risk for Alzheimer's. Participants with cognitive complaints and a family history of Alzheimer's will be randomly assigned to active or sham groups. Over 12 weeks, the effects on memory, executive function, ATP levels, and brain connectivity will be assessed, along with exploring factors like genetics and brain imaging in response to treatment.

In collaboration with the University of Florida, the University of Arizona, and the National Institute on Aging (NIA)

See study information

Mild Cognitive Impairment Ongoing

Recruiting Recruitment (n=60)

Conducted with the

Neuro Gamma

Mild Cognitive Impairment (MCI) Clinical Trial Recruitment | University of Toronto | Unity Health Toronto | Vielight Neuro (n=60)

Toronto MCI clinical study seeks adults based in Toronto, aged 50+ and noticing memory changes (no diagnosis) to try a 12-week, non-drug photobiomodulation (near-infrared light) helmet. To check eligibility, contact 416-360-4000 ext. 47838 or memoryclinic@unityhealth.to

In collaboration with the University of Toronto and Unity Health, St. Michael’s Hospital.

Join study Clinicaltrials.gov

Scientific collaboration portfolio & achievements

Physiology

Immune system

Upper respiratory tract
Acute COVID
Sleep
Pain

Basic science

Cellular structures

Microtubules/tubulin
Neurons and networks

Brain response

fMRI
Structural MRI
DTI33
In Silico
EEG

Biomarkers

Serum biomarkers
MR spectroscopy
Raman spectroscopy
EEG-based
Transcranial magnetic stimulation-based

Neurology

Psychotherapy

Substance abuse
ADHD

Neurology

Traumatic brain injury
Alzheimer’s/MCI
Parkinson’s
Brain fog in Long covid
Stroke
Gulf War Illness

Psychiatry

Depression
Bipolar depression
Autism
Addiction
Intimate partner violence
Developmental trauma
PTSD

Performance

Sports

Performance
Traumatic brain injury recovery

Cognition & creativity

Cognition
Performance arts

Meditation & mindfulness

Altered states

Innovative research with leading institutions

Learn more about the breakthroughs in photobiomodulation research powered by Vielight’s collaborations with healthcare and educational institutions

TBI Testimonial | Dr. Larry Carr, Former BYU Linebacker (Brain Photobiomodulation)

From TBI to Recovery: 
PBM Research Breakthrough

Dr. Larry Carr, a former BYU football player, developed symptoms due to football-related brain injuries, which affected his cognitive and emotional health. He discovered the Vielight Neuro device and, under guidance from researchers at the University of Utah, underwent brain photobiomodulation research. He became an advocate for the device, participating in studies at BYU and the University of Utah.

Researchers at the University of Utah, in collaboration with Mount Sinai Hospital, also conducted clinical trials with the Vielight Neuro. Their first independent study, involving 43 participants, found that intranasal photobiomodulation therapy improved reaction time, grip strength, and neuromuscular function.

These positive findings led to further studies, including those utilizing fMRI and BOLD imaging, which are currently under analysis and pending publication, with the goal of understanding the broader impacts of PBM on CTE and TBI.

See full article

Parkinsons PBM Clinical Results [Vielight Neuro Gamma / Irradia MID 2.5]

First Research Study to Show Photobiomodulation’s Promise for Parkinson's

In a groundbreaking indendent study led by Dr. Ann Liebert and her team at the University of Sydney, the Vielight Neuro Gamma device was used for transcranial-intranasal brain photobiomodulation to treat Parkinson’s disease. This study marked the first brain PBM trial to show positive clinical results for this condition. Twelve participants with idiopathic Parkinson’s disease received 12 weeks of PBM treatment, including transcranial, intranasal, neck, and abdominal applications.

The study assessed mobility, fine motor skills, balance, and cognition at several stages: baseline, after 4 weeks, after 12 weeks, and after a home treatment period. Results showed significant improvements (p < 0.05) in mobility, cognition, dynamic balance, and fine motor skills, with these benefits lasting up to one year. Continued home use maintained improvements, indicating the treatment’s long-lasting effect. A minor Hawthorne Effect was noted, but it was less impactful than the treatment itself. No adverse side effects were reported throughout the study.

See full article

Accelerated Viral Recovery Major Clinical Trial Results | 294 Participants

Accelerated Recovery from Viral Infections: 
Photobiomodulation Research

The Vielight RX-Plus is the only photobiomodulation device supported by published clinical results for viral recovery and inflammatory-based immunity. The device is licensed by Health Canada to help speed up recovery from upper respiratory infections like COVID-19.

A major clinical trial with 294 participants tested the Vielight RX-Plus device to see how well it helps with recovery from viral infections, like COVID-19, focusing on reducing recovery time and improving symptoms.

This major clinical trial showed that patients with symptoms for 0-7 days recovered faster when using the Vielight RX-Plus alongside regular treatment. Photobiomodulation therapy effectively reduced symptoms like headache, chest congestion, body aches, high heart rate, and taste problems, particularly for those with shorter symptom durations. Photobiomodulation is believed to speed up recovery by lowering inflammation and cytokine levels in the body.

See full article

Vielight Neuro – Dementia and Brain Photobiomodulation Research

New Research: Brain Stimulation Boosts Brain Connectivity

Dr. Linda Chao at the University of California, San Francisco conducted an independent study to verify the results of a 2015 dementia pilot trial using the Vielight Neuro Gamma for brain photobiomodulation in dementia patients. Eight participants were randomly assigned to either 12 weeks of usual care or home photobiomodulaton treatment using the Vielight Neuro Gamma. The study involved various assessments, including the Alzheimer’s Disease Assessment Scale (ADAS-cog) and neuropsychiatric evaluations.

The photobiomodulation group showed significant improvements in cognitive function and behavior, with a reduction in dementia-related behaviors compared to baseline scores. This group also had increased functional connectivity, particularly in the parietal regions, and improved functional connectivity in the default mode network. This is the first report of such functional connectivity improvements following a non-pharmacological intervention. The study found no adverse side effects.

See full article

The Vielight Neuro Explained | Inventor and Research Scientists

Revolutionizing Alzheimer’s Research: Neuromodulation

Recent Alzheimer’s research has highlighted a breakthrough with the Vielight Neuro Gamma, the first brain photobiomodulation device to demonstrate neuromodulation as of January 2018. Using high-irradiance Vie-LED modules targeting the brain’s Default Mode Network, a key study found that a single session of 40Hz 810nm near-infrared energy increased higher frequencies (gamma, alpha, beta) and decreased slower frequencies (delta, theta), proving that photobiomodulation can modulate neuronal oscillations.

Building on this, an independent study from the University of California San Francisco showed that 12 weeks of at-home use of the Neuro Gamma in dementia patients led to significant improvements in mental acuity and enhanced connectivity between the posterior cingulate cortex and parietal nodes within the Default Mode Network.

See published study